← Back to Search

Anti-rheumatic agent

Leflunomide for Lymphoproliferative Disorder

Phase 2
Waitlist Available
Led By Christiane Querfeld
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months post treatment
Awards & highlights

Study Summary

This trial studies leflunomide for the treatment of relapsed or refractory CD30+ lymphoproliferative disorders. Leflunomide may stop cancer cell growth by blocking enzymes needed for cell growth.

Eligible Conditions
  • Lymphoproliferative Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Response Rate
Secondary outcome measures
Complete Response Rate
Other outcome measures
Micro (mi)R ribonucleic acid (RNA)/messenger (m)RNA expression profile

Side effects data

From 2015 Phase 4 trial • 400 Patients • NCT01172639
33%
Upper respiratory tract infection
26%
Abdominal pain
23%
Nausea
19%
Gastroenteritis
16%
Hairloss
14%
Liver function disturbance
12%
Tendinopathy
12%
Arthralgia
9%
Vertigo
9%
Hypertension
9%
Eczema
7%
Increased transpiration
7%
Arthrosis
7%
Back pain
7%
Agitation
7%
Tooth extraction
7%
Paresthesia
7%
Pruritus
5%
Anaemia
5%
Venous insufficiency
5%
Palpitations
5%
Sjogren's disease
5%
Muscle cramps
5%
Influenza infection
5%
Fatigue
5%
Headache
5%
Bronchitis
5%
General malaise
5%
Arthritis
5%
Flushes
2%
Pyrosis
2%
Endometrioid adenocarcinoma
2%
Intervertebral disc disorder
2%
Rotator cuff lesion
2%
Bladder infection
2%
Eye infection
2%
Insomnia
2%
Diarrhoea
2%
Angina
2%
Kidney cancer malignant
2%
Pneumonia
2%
Cough
2%
Genital infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
CoBRA Slim Low Risk Group
Tight Step Up Low Risk Group
CoBRA Classic High Risk Group
CoBRA Slim High Risk Group
CoBRA Avant-garde High Risk Group

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (leflunomide)Experimental Treatment1 Intervention
Patients receive leflunomide PO QD on days 1-28. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Leflunomide
2003
Completed Phase 4
~1670

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
565 Previous Clinical Trials
1,921,459 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,662 Previous Clinical Trials
40,925,880 Total Patients Enrolled
Christiane QuerfeldPrincipal InvestigatorCity of Hope Medical Center
1 Previous Clinical Trials
1,250 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we still able to sign people up for this research project?

"The clinicaltrials.gov website shows that this study is not recruiting patients at the moment. However, it's worth noting that the trial was initially posted on May 5th, 2021 and updated as recently as September 26th, 2022. Additionally, there are 999 other trials currently looking for participants."

Answered by AI

Are there other cases in which Leflunomide has been studied?

"Leflunomide is being studied in 16 active clinical trials, 2 of which are Phase 3. Most of the research surrounding this medication is taking place in Duarte, California; however, there are 29 locations running Leflunomide trials."

Answered by AI

How many people can join this trial at most?

"Presently, this study is not open for recruitment. However, it was first posted on May 5th, 2021 and was last edited on September 26th, 2022. For those looking for other studies, 983 clinical trials are actively recruiting patients with lymphoproliferative disorders and 16 studies for leflunomide are also seeking participants."

Answered by AI

Is Leflunomide cleared by the FDA for use?

"Because there is only some data supporting safety, and none supporting efficacy, our team has given Leflunomide a score of 2."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders
2021. "Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04463615.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top